Acne Vulgaris Clinical Trial
Official title:
A Multi-Center, Evaluator Blinded, Randomized Clinical Study to Evaluate the Efficacy and Tolerance of Two Acne Treatment Regimens on Subjects With Mild to Moderate Acne Vulgaris
This study will compare two different acne treatment regimens for the treatment of acne. Half of participants will receive a cleanser and a light therapy mask, while half of the participants will receive a cleanser, a light therapy topical gel-cream, and a light therapy mask.
Acne vulgaris is a common chronic skin disease involving blockage and/or inflammation of the
hair follicles and their accompany sebaceous glands.
Research has shown the benefits of red and blue light therapy in the treatment of mild to
moderate acne, with red and blue light shown to target acne-causing bacteria and have an
effect on inflammation reduction.
Light-based therapies have been used successfully to treat dermatological conditions since
the early 1900s, with various parts of the electromagnetic spectrum (i.e. ultraviolet [UV],
visible, near-infrared, etc.) demonstrating different benefits. Light-emitting diodes (LEDs)
offer delivery of light to the skin in a gentler manner as compared to light delivered by
lasers, primarily due to the lower energy output. It has been reported that LEDs do not
deliver enough power to damage tissues and do not have the same risk of accidental eye damage
that lasers do. Visible-LED light therapy has been deemed a non-significant risk by the U.S.
Food and Drug Administration (FDA) and has been approved for use in humans.
It is well established in the literature that visible light penetration into the epidermal
and dermal layers of human skin is primarily governed by absorption and scattering events,
with the latter being the more impactful of the two. Visible light penetration into human
skin can be increased by reducing scattering. This can be accomplished by temporary hydrogen
bonding disruption, which leads to the reversible rearrangement of epidermal and dermal
structures that cause scattering. Glycerol (i.e. glycerin) is hypothesized to generate the
level of hydrogen bonding disruption described above, and therefore will be investigated in
the present study.
This study will look to evaluate and then compare the acne clearing efficacy and tolerance of
two different acne treatment regimens - a cleanser used with a currently marketed red and
blue light acne light therapy mask alone vs. the cleanser used with the same mask in
conjunction with a light therapy topical gel-cream - to determine the efficacy of these
treatments and then to assess if the efficacy of the light therapy mask used with the topical
gel-cream treatment is non-inferior to the mask alone in the reduction of lesions in mild to
moderate acne. If non-inferiority is demonstrated, the mask with topical gel-cream treatment
will be further assessed for its superiority to the mask alone.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04321070 -
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
|
Phase 1 | |
Recruiting |
NCT05755256 -
The Impact of Probiotics on Skin Hydration in Youth With Mild Acne
|
Phase 2 | |
Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01445301 -
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
|
Phase 3 | |
Completed |
NCT03303170 -
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
|
N/A | |
Completed |
NCT04698239 -
Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.
|
N/A | |
Completed |
NCT02886715 -
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
|
Phase 3 | |
Terminated |
NCT02924428 -
Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris
|
N/A | |
Completed |
NCT02709902 -
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
|
Phase 1 | |
Not yet recruiting |
NCT02535871 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Not yet recruiting |
NCT02491060 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Not yet recruiting |
NCT02525822 -
Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris
|
Phase 2 | |
Completed |
NCT02913001 -
The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne
|
N/A | |
Completed |
NCT02250430 -
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
|
Phase 1 | |
Completed |
NCT01769664 -
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01694810 -
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01727440 -
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
|
N/A | |
Completed |
NCT01194375 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
|
Phase 2 | |
Completed |
NCT02524665 -
8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne
|
Phase 4 | |
Completed |
NCT01706250 -
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
|
Phase 4 |